Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5998581 | MELINTA THERAP | Reductive alkylation of glycopeptide antibiotics |
Nov, 2017
(6 years ago) | |
US5840684 | MELINTA THERAP | Glycopeptide antibiotic derivatives |
Nov, 2020
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(5 years from now) | |
US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(5 years from now) | |
US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(11 years from now) |
Orbactiv is owned by Melinta Therap.
Orbactiv contains Oritavancin Diphosphate.
Orbactiv has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Orbactiv are:
Orbactiv was authorised for market use on 06 August, 2014.
Orbactiv is available in powder;intravenous dosage forms.
Orbactiv can be used as treatment of bacterial skin and skin structure infections using a single dose, treatment of bacterial skin and skin structure infections.
Drug patent challenges can be filed against Orbactiv from 07 August, 2023.
The generics of Orbactiv are possible to be released after 16 July, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections
Dosage: POWDER;INTRAVENOUS